RETINA

McLEOD, DAVID

RETINA. 29(10):1381-1395, November/December 2009.

doi: 10.1097/IAE.0b013e3181b85f41

The clinical and fundus fluorescein angiographic characteristics of cilioretinal infarction combined with retinal vein occlusion are reviewed, and the pathophysiological mechanisms previously put forward to explain their association are critically appraised. Two related hypotheses that elucidate the interrelationship-branch flow exclusion and choroidal arterial steal-are presented.

Abstract:

WU, LIHTEH; AREVALO, J FERNANDO; BERROCAL, MARIA H.; MAIA, MAURICIO; ROCA, JOSÉ A.; MORALES-CANTÓN, VIRGILIO; ALEZZANDRINI, ARTURO A.; DÍAZ-LLOPIS, MANUEL J.

RETINA. 29(10):1396-1403, November/December 2009.

doi: 10.1097/IAE.0b013e3181bcef53

Vascular endothelial growth factor inhibition up to 2 years appears to be beneficial in eyes with macular edema secondary to branch retinal vein occlusion. Reinjections will be necessary in a large number of eyes to maintain a lasting beneficial effect. Increasing the usual dose of 1.25 mg to 2.5 mg of bevacizumab does not appear to add any additional benefit in terms of visual acuity or injection burden.

Abstract:

BANAEE, TOUKA

RETINA. 29(10):1535, November/December 2009.

doi: 10.1097/IAE.0b013e3181b834a6

Sisk, Robert A.; Berrocal, Audina M.; Albini, Thomas A.; Stanciu, Natalie; Gottlieb, Justin L.; El Rayes, Ehab

RETINA. 29(10):1538-1541, November/December 2009.

doi: 10.1097/IAE.0b013e3181ba2456

KURIHARA, TOSHIHIDE; SUZUKI, KOTARO; NODA, KOUSUKE; KAWAMURA, RYOSUKE; NAGAI, NORIHIRO; SHINODA, HAJIME; SHINODA, KEI; TSUBOTA, KAZUO; ISHIDA, SUSUMU; INOUE, MAKOTO

RETINA. 29(10):1542-1544, November/December 2009.

doi: 10.1097/IAE.0b013e3181bcef0e

WONG, MARGARET; JANOWICZ, MARK; TESSLER, HOWARD H.; GOLDSTEIN, DEBRA A.

RETINA. 29(10):1545-1546, November/December 2009.

doi: 10.1097/IAE.0b013e3181bd2ffc

Romano, Mario R.

RETINA. 29(10):1547, November/December 2009.

doi: 10.1097/IAE.0b013e3181b7746a